Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (331-340 of 564) with videos related to

Pageof 57
Sort By:
European Urology|April 18, 2001
Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patientsS G Williams, R Gandour-Edwards, A D Deitch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapyMatthew D Galsky, Noah M Hahn, Jonathan Rosenberg, et al.
Japanese Journal of Clinical Oncology|March 19, 2021
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive diseaseHiroyoshi Suzuki, Daniel Castellano, Johann de Bono, et al.
JAMA Oncology|December 13, 2019
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical TrialsAndrew J Armstrong, Mohammed Al-Adhami, Ping Lin, et al.
JAMA Oncology|May 26, 2018
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAndrew J Armstrong, Aseem Anand, Lars Edenbrandt, et al.
Journal of the National Cancer Institute|October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapySusan Halabi, Chen-Yen Lin, Eric J Small, et al.
Cancers|December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical TrialsBertrand Tombal, Arnulf Stenzl, David Cella, et al.
The Journal of Urology|March 1, 1988
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumorsH I Scher, A Yagoda, H W Herr, et al.
Progress in Clinical and Biological Research|January 1, 1988
Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapyC N Sternberg, A Yagoda, H I Scher, et al.
Pageof 57

Showing results (331-340 of 564) with videos related to

Sort By:
Pageof 57
European Urology|April 18, 2001
Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patientsS G Williams, R Gandour-Edwards, A D Deitch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapyMatthew D Galsky, Noah M Hahn, Jonathan Rosenberg, et al.
Japanese Journal of Clinical Oncology|March 19, 2021
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive diseaseHiroyoshi Suzuki, Daniel Castellano, Johann de Bono, et al.
JAMA Oncology|December 13, 2019
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical TrialsAndrew J Armstrong, Mohammed Al-Adhami, Ping Lin, et al.
JAMA Oncology|May 26, 2018
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAndrew J Armstrong, Aseem Anand, Lars Edenbrandt, et al.
Journal of the National Cancer Institute|October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapySusan Halabi, Chen-Yen Lin, Eric J Small, et al.
Cancers|December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical TrialsBertrand Tombal, Arnulf Stenzl, David Cella, et al.
The Journal of Urology|March 1, 1988
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumorsH I Scher, A Yagoda, H W Herr, et al.
Progress in Clinical and Biological Research|January 1, 1988
Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapyC N Sternberg, A Yagoda, H I Scher, et al.
Pageof 57